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Summary
Nearly half of HLA-A2-positive individuals in African populations have a subtype of HLA-A2
other than the A*0201 allele. We have isolated the common African HLA-A2 subtype genes
from Epstein-Barr virus-transformed B cell lines and have established stable class I reduced
transfectants expressing these alleles. We have studied the peptide binding and presentation
properties ofA*0201, A*0202, A*0205, A*0214, and A*6901 by a combination ofapproaches:
assaying direct binding oflabeled synthetic peptides, studying the ability of antigen-specific cy-
totoxic T lymphocytes to recognize peptide-pulsed cells, and sequencing peptide pools and in-
dividual ligands eluted from cells. We find that A*0201-restricted peptides can also bind to
A*0202 but do not bind strongly to the other alleles in this study. We show that some cyto-
toxic T lymphocytes can recognize all subtypes capable ofbinding an antigenic peptide, whereas
others are subtype specific. Sequencing of eluted peptides reveals that A*0202 has a similar
peptide motif to A*0201, but that A*0205, A*0214, and A*6901 have different motifs. These
data strongly support a model in which residue 9 (Phe or Tyr) ofthe A2/A68/A69 molecules is
a critical factor in determining the specificity of the B pocket of the major histocompatibility
complex and the position 2 anchor residue of associated peptides. We conclude that a single-
amino acid difference in the major histocompatibility complex can be sufficient to cause a dra-
matic change in the nature of bound peptides, implying that individuals with closely related
HLA subtypes may present very different repertoires of antigenic peptides to T cells in an im-
mune response. It is likely to be a general phenomenon that very similar class I subtypes will
behave as functionally distinct HLA allotypes.
H
LA class I molecules are highly polymorphic cell-sur-
face glycoproteins that present antigenic peptides to
CTLs (1). HLA-A2 is the most common class I allele de-
fined by serology and consists of at least 16 closely related
subtypes that differ by 1-5 amino acids (2, 3) . The A*0201
allele has been studied extensively, and its high resolution
crystal structure (4, 5) and peptide binding properties (6-8)
are known. Far less is known about the other A2 subtypes.
No individual ligands have been previously reported, and
none of their pool sequence motifs have been determined,
with the exception of A*0205 (9). The polymorphisms of
the A2 subtypes are concentrated in the peptide-binding
groove of the molecules (10), and several reports show that
antigen-specific CTLs can fail to recognize certain HLA-
A2 subtypes pulsed with the antigenic peptide (11, 12) . It
has been unclear, however, whether these observations are
due to differences in the ability of the subtypes to bind the
peptides or to conformational differences in the presenta-
tion ofthese peptides to CTL.
With the recent finding that the HLA-A2 subtypes are
very common in non-Caucasian populations (13), the im-
portance in determining their peptide binding and presen-
tation properties has greatly increased. Such knowledge is
crucial for studying the T cell response in diseases in Africa
and Asia. Population studies have shown that, among HLA-
A2-positive individuals, the non-A*0201 subtypes are rela-
tively infrequent in most Caucasian populations (-5% of
A2-positive individuals) but much more abundant in other
populations (13) . In Singapore Chinese, the most common
HLA-A2 subtypes are reported to be A*0207 (45%),
A*0201 (23%), A*0203 (23%), and A*0206 (8%) (13). In a
study of Black Africans from both East and West Africa, the
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(22%), A*0205 (14%), and A*0214 (3%) (13). A study lim-
ited to Black Africans from Kenya shows slightly different
frequencies, with A*0201 (55%), A*0202 (25%), A*0214
(12%), and A*0205 (8%) most common, and a geographi-
cally isolated Caucasianpopulation from Sardinia also shows
an interesting distribution, with A*0201 (59%) andA*0205
(41%) as the major HLA-A2 subtypes (13a). We have
focused our study on the common African HLA-A2 sub-
types and have also included A*6901 for its similarity to
A*0201 .
Because homozygous B cell lines were not available, we
established transfectant cell lines expressing these alleles.
We chose class I reduced (ClR)l cells as the ideal recipient
cell line for all the class I genes (14, 15) since they have very
low levels of HLA-A,B expression. In this paper, we report
peptide binding studies, CTL killing assays, and peptide elu-
tion studies using these transfectants. The combination of
these techniques has led to a detailed picture of the ability
of the HLA-A2 subtypes to bind and to present peptides.
We find that very small changes in the HLA-A2 molecule,
especially if these differences are located in the specificity
pockets of the peptide-binding groove, can dramatically al-
terits ability to bind exogenouspeptides, to react with CTLs,
and to present endogenous peptides.
Materials and Methods
Cells, Synthetic Peptides, andAntibodies.
￿
C1R cells, which were
produced from the human B lymphoblastoid line Licr.Lon.Hmy2
(14-16), were used as the recipient for the transfectant class I
genes. EBV-transformed B cell lines from a number of African
individuals were obtained from Dr. F. Gotch. Cells were grown
at 37°C with 5% carbon dioxide in RPMI 1640 (Sigma Chemical
Co., St. Louis, MO) supplemented with 10% FCS, 2 mM L-gluta-
mine, 100 IU/ml penicillin, and 100 Ltg/ml streptomycin. Peptides
were obtained from the MedicalResearch CouncilAIDS Reagent
Project (NIBSC, South Minims, UK) or were synthesized using
standard Fmoc chemistry on a peptide synthesizer (SMPS 350;
Advanced Chem Tech UK, Cambridge, UK), purified by re-
verse-phase HPLC, and checkedby mass spectrometry. The pep-
tides used were as follows: pol HIV-1 reverse transcriptase 476-
484, ILKEPVHGV (17); gag HIV-1 p17 77-85, SLYNTVATL
(18) ; influenza matrix protein 58-66, GILGFVFTL (19, 20); a sol-
uble, iodinatable derivative ofthe influenza matrix peptide, YGI-
LGKVFTL, that has been shown to have identical binding prop-
erties as the native peptide (21-23); and the hepatitis B virus
(HBV) core protein 18-27, modified foriodination (F6Y), FLPS-
DYFPSV (24, 25). mAbs were affinity purified on protein A-Seph-
arose beads (Sigma Chemical Co.) from hybridoma supernatant
by standard procedures and included W6/32 (anti-class I mono-
morphic;26), BB7.2 (anti-A2/A69; 27), MA2.1 (anti-A2/B17; 28),
andME1 (anti-137/1322/1327; 29).
Molecular Cloning of the HLA-A2 Subtypes and Establishing Stable
Transfectant Cell Lines. DNA cloning techniques were performed
essentially as described (30). 5 X 106EBV-transformedB cells from
lAbbreviations used in thispaper: Clk, class Ireduced; HBV, hepatitis B virus.
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anumber ofAfrican individuals were treatedwith RNAzol B (Bio-
genesis Ltd., Bournemouth, UK) according to the manufacturer's
instructions, andtotal cellular messenger RNA was alcohol precip-
itated and resuspended in diethylpyrocarbonate-treated water.
cDNA was synthesized with reverse transcriptase using an oligo-
dT primer (Collaborative Research Inc., Lexington, MA), and
the complete HLA-A locus alleles were specifically amplified by
the PCR using synthetic oligonucleotide primers. The forward
primer (5' GTC GAA TTC GCC GCC ATG GCC GTC ATG
GCG CCC CGA 3') and reverse primer (5' CGC GGA TCC
TCA TCA CAC TTT ACAAGC TGT 3') included engineered
restriction sites that facilitated cloning of the PCR products as
EcoRI/BamHI fragments into M13 bacteriophage (Boehringer
Mannheim Corp.) . After total sequencing of individual clones and
identification of the desired HLA-A2 subtype alleles, the genes
were subdoned into pBluescript II KS(-) (Stratagene, La Jolla,
CA) and then cloned as HindlII/BamHI fragments into the ex-
pression vector pKG4 (obtained from Dr. A. Townsend, Institute
of Molecular Medicine, Oxford, UK). 20 jig of CsCl-purified
plasmid DNA was used to transfect 10' ClR cells by electropora-
tion (Gene Pulser system; Bio-Rad Laboratories, Richmond, CA).
After 24 h, 1.8 mg/ml geneticin G-418 sulfate (GIBCO BRL,
Gaithersburg, MD) was added to select for transfectants, and cell
growth was observed after 3wk. High-expressinglineswere estab-
lished by sorting the cells with 13137.2-coated sheep anti-mouse
dynabeads (Dynal, Inc., GreatNeck, NY) according to the manu-
facturer's instructions. High-expressing clones were established
by limiting dilution in 96-well plates. Expression of the trans-
fected genes was monitored regularly throughout the study by
flow cytometry (Becton Dickinson & Co., Cockeysville, MD)
using a panel of mAbs and an FITC-conjugated anti-mouse sec-
ondary antibody accordingto standard protocols.
Peptide Binding Assay.
￿
Binding of synthetic peptides to HLA
molecules in cell lysates was assayed essentially as described (23).
Peptides were iodinated on either histidine or tyrosine by incu-
bating 1 N,g peptide in 100 RI PBS for 60 s with 0.5 MCi of 1251
(Amersham Corp., Arlington Heights, IL) and 10 lt.l of 5 mg/ml
chloramine T. The reaction was terminated by the addition of30
p.l of 5 mg/ml sodium metabisulfate and 2.5 ml of 10 mM Tris-
HCI, pH 7.5, 0.15 M NaCl, 0.1% NP-40, 0.1% BSA, and 0.2%
sodium azide, and the labeled peptide was purified on a gel filtra-
tion Sephadex G-25 column (Pharmacia Biotech, Inc., Piscataway,
NJ). 107 C1R cells expressing a class I allele were washed twice in
PBS, starved for 1 h in methionine-free media, metabolically la-
beled with 100 NLCi of [35S]methionine (Amersham Corp.) for2 h,
and lysed for 30 min on ice in 1 ml of20 mM Tris-HCI, pH 7.5,
0.15 M NaCl, and 0.5% NP-40. The lysates were centrifuged for
15 minin a microfuge, and 100 RI of 10% insolubilized protein A
(Sigma Chemical Co.) and 1 X 105 to 5 X 106 cpm of labeled
peptide were added to the supernatant. After an overnight incu-
bation at 4°C andcentrifugation as before, 15 N,gofpurified BB7.2
(orW6/32 for the ClR-137 control experiments) was added. Af-
terincubation for 1 h, the class I complexes were immunoprecip-
itated with 100 ltl of 50 mg/ml protein A-Sepharose beads,
washed three times in lysis buffer, and analyzed by reducing SDS-
PAGE on a 16.5%gel. The gels were fixed, dried, and exposed to
autoradiographic film, and the intensities of the heavy chain and
peptide bands were quantitated by scanning densitometry. The
quantitation of peptide binding normalized to the amount of
heavy chain present was calculated by the following formula:
(peptide intensity - background)/(heavy chain intensity - back-
ground). We estimate the peptide concentrations in the binding
assay to be ^100 pM (105 cpm) to 5 nM (5 X 106 cpm).CTL Recognition Assay.
￿
Standard 5'Crrelease assays were per-
formed (21) using two established peptide-specific CTL clones or
lines, which were generated essentially as described (31, 32). Tar-
get cells were washed with PBSand labeled with 100 pCi of "Cr
(Amersham Corp.) for 1 h at 37°C. Afterwashing, the target cells
were plated at 5 X 103/well with peptide and CTL, media alone,
or 5% Triton X-100 in a total reaction volume of 165 N1/well.
After 5 h at 37°C, 20-p,l aliquots were removed, andthe radioac-
tivity release was determined using a beta-plate counter. The per-
cent specific lysis was calculated accordingto the following formula:
(experimental cpm - mediarelease)/(triton release - mediarelease).
Elution and Sequencing ofSelfPeptides.
￿
HLA-binding peptides
were TFA-extracted from ClR transfectant cell lines essentially
as described (6). 2 X 1010 cells were lysed in PBS/1% NP-40
with protease inhibitors for 2 h stirring in an ice bath. The lysate
was homogenized, sonicated, centrifuged at 3,500 rpm for 10 min,
and ultracentrifuged at 100,000gfor 1 h. Afterfiltration, the cleared
lysate was passed over a 2-ml pre-column ofglycine-blocked Sepha-
rose beads and a 4-ml immunoaffinity column of CNBr-activated
Sepharosebeads (Pharmacia Biotech, Inc.) linked to purified BB7.2
antibody. Both columnswere washed with PBS/0.5%NP-40, PBS/
0.1% NP-40, and PBS, and the peptides were extracted with 0.1%
TFA. The TFAextracts were passed through a Centricon-10 (Am-
icon Inc., Beverly, MA) apparatus to remove large proteins, and
the peptides were separatedby reverse-phase HPLC (SMART sys-
tem; PharmaciaBiotech, Inc.) on a ILRPC C2/C18 column (2.1 X
100 mm). Pool sequences andindividual peptide ligands were de-
termined by Edman degradation sequencing using a protein se-
quencer (476A; Applied Biosystems, Inc., Foster City, CA).
A
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Results
C1R Transfectants.
￿
ClR cells stably transfected with the
HLA-A*0202, A*0205, and A*0214 alleles (sequence poly-
morphisms are detailed in Fig. 1 A) were established. Flow
cytometry FRCS' analysis was used to monitor surface ex-
pression; the expression levels of all the transfectants were
approximately equal. All cell lines were stained with puri-
fied W6/32, BB7.2, MA2.1, and ME1 antibodies (26-29)
with the expected results (data not shown), and expression
levels were monitored regularly. Fig. 1 B shows a typical
staining of one cell line.
Binding ofA*0201-restricted Peptides.
￿
The abilities ofthe
HLA-A2 subtypes and of HLA-A69 to bind three A*0201-
restricted peptides (the pol, gag, and modified flu matrix pep-
tides) were studied using the binding assay and calculations
detailed in Materials and Methods. The gels in Fig. 2 clearly
show the 35S-labeled heavy chain and the 1251-labeled pep-
tide in each experiment, and Fig. 2 Eshows the quantitated
peptide binding, which is calculated relative to the amount
of heavy chain present. The [32-microglobuhn band was oc-
casionally weak because this protein is often poorly labeled
with [35S]methionine. Note that thepeptides (-1 kD) have
anomalous molecularweights on these gels because of their
charges and nonlinear binding of SDS. As depicted in Fig.
2, all three peptides were able to bind well to A*0201, and
none could bind to the negative control B*0701, also ex-
ME1 BB7.2
Figure 1 .
￿
ClK transfectants expressing HLA-A2 subtypes. (A) Comparison of the amino acid differences ofA*0201, A*0202, A*0205, andA*0214
andtheir positions in thepeptide-binding groove of the HLA-A2 molecule (4, 5) . (B) Sample FACScan® profiles of ME1 or 13137.2 staining ofuntrans-
¬ectedClRcells or CIR-A*0202 cells. 13137.2 staining ofthe A2 subtype transfectants was -100-200 times background staining.
Subtype
r4tC
9
polymorhpic
43 95
residues :
156
A*0201 F 0 V L
A*0202 F R L W
A-0205 Y R L W
A*0214 Y R L LFigure 2 .
￿
In vitro binding assays oflabeled synthetic peptide to class I molecules in cell lysates. 16.5% SDS-PAGE analysis ofimmunoprecipitates from
binding assays shows the presence ofthe 35S-labeled class I heavy chain and possible associated "'I-labeled peptide . The pol peptide (A, D), the gag pep-
tide (B, D), and the modified flu matrix peptide (C, D) were assayed for binding to the A*0201, A*0202, and A*0205 molecules (A-C) as well as to the
A*0214 and A*6901 molecules (D) . The asterisk denotes the iodinated position in the peptide . In A-C, free peptide is shown in lane 1, and the binding
assays used 10 5 cpm (lanes 2, 6, and 10), 5 X 105cpm (lanes 3, 7, and 11), 2 X 10 6 cpm (lanes 4, 8, and 12), and 5 X 106cpm (lanes 5, 9, 13-15) peptide .
Cell lines were CIR-A*0201 (lanes 2-5), ClR-A*0202 (lanes 6-9), ClR-A*0205 (lanes 10-13), untransfected ClR (lane 14), and CIR-B*0701 (lane
15) . In D, 2 X 106 cpm pol peptide (lanes 1, 4, 7, and 10), gag peptide (lanes 2, 5, 8, and 11), or modified flu matrix peptide (lanes 3, 6, 9, and 12) were
examined for binding to lysates from ClR-A*0201 (lanes 1-3), CIR-A*0214 (lanes 4-6), ClR-A*6901 (lanes 7-9), and ClR-B*0701 (lanes 10-12)
cells . In E, the quantitated peptide binding from the assays is shown (see Materials and Methods) .
pressed in CIR cells . (The contribution ofHLA-C to the
intensity of the heavy-chain band in the CIR-B7 lanes, in
which the immunoprecipitation usesW6/32, is minimal [data
not shown] according to flow cytometry.) All three pep-
tides also bound A*0202 well, but they did not in general
react strongly with A*0205 and A*0214 . The flu matrix
peptide bound weakly to A*0205, and very long exposures
of the autoradiographic films (data not shown) suggest that
there is a very low level ofreactivity of the flu matrix pep-
tide for A*0214 and of the pol peptide for both A*0205
and A*0214 . No reactivity whatsoever was observed for
the gag peptide for A*0205 and A*0214 using this assay .
The pol and gag peptides also did not bind A*6901, but the
flu matrix peptide did bind A*6901 very well (Fig. 2 D) .
CTL Recognition ofHLA-A2 Subtypes .
￿
Two antigen-spe-
cific CTLs, one specific for the pol peptide and one for the
flu matrix peptide, were tested for their ability to lyse the
C 1R transfectants pulsed with various concentrations of syn-
thetic peptides . Both CTLs were totally peptide specific (data
not shown) . The pol-specific CTL clone recognized the pol
peptide presented by ClR-A*0201 and CIR-A*0202 cells
equally well, had a low level of recognition of pol-pulsed
ClR-A*0205 cells, but did not recognize pol-pulsed ClR-
A*0214 and ClR-B*0701 cells (Fig . 3 A) . Note that this
killing pattern correlates very closely with the ability of the
A2 subtypes to bind this peptide (Fig . 2) . The inhibition of
1850
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killing at high peptide concentrations is probably due to a
slight toxicity of the peptide . The flu matrix-specific CTL
line recognized only matrix-pulsed ClR-A*0201 well, and
had only a very weak recognition of ClR-A*0202 at very
high peptide concentrations (Fig . 3 B) . Because A*0202 can
bind the flu matrix peptide quite well (Fig. 2 C) but cannot
present it in a manner that is recognized well by the CTL,
this CTL line appears to be subtype specific .
Sequencing of Eluted Peptides .
￿
Edman sequencing of the
peptides naturally presented by the ClR transfectants re-
vealed clear peptide motifs (6) as well as several individual
ligands for most subtypes . Fig . 4 depicts the sequencing re-
sults, indicating the pool sequence anchor residues (in
bold), auxiliary anchors, and preferred residues, as well as
the individual ligands and their presumed source proteins .
In the raw data (not shown), all the peptide position 2 (P2)
anchors were 100-1,500% over the corresponding signal in
the first (P1) sequencing cycle and were >100 pmol in
quantity. Previous work has shown that A*0201 has a Leu
anchor at P2 and Val/Leu at P9 (6), and that A*6801 has a
Val/Thr anchor at P2 and Arg/Lys at P9 (33) . A*0202 was
found to have anchors very similar to A*0201 (Leu at P2
and Leu/Val at P9), but A*0205 and A*0214 had signifi-
cantly different motifs (Val/Gln/Leu at P2 and Leu at P9) .
A previous determination of the A*0205 motif is very sim-
ilar to the one presented here (9) . A*6901, which is a classA
B
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Figure 3.
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CTL recognition of HLA-A2 subtypes by peptide titration
curves. (A) Recognition of pol peptide-pulsed CIR transfectants by a
pol-specific CTL clone using an E/T ratio of6:1. (B) Recognition ofma-
trix-pulsed ClR transfectants by a flu matrix-specific CTL line using an
E/T ratio of 15:1 . --*-, A*0201; -0-, A*0202; f, A*0205; -[}-,
A*0214; -7~,- , B*0701 .
I allele consisting of the a1 domain of A*6801 and the ot2
domain of A*0201, had an interesting motif that was essen-
tially the P2 anchor of A*6801 (Val/Thr/Ala) and the P9
anchor ofA*0201 (Val/Leu). The preferred residues in other
positions seemed generally to reflect the trends of A*0201,
including a hydrophobic residue at P3, a polar residue at
P4, and a hydrophobic residue at P6 . In addition, A*6901
had a very strong Glu signal at P1, which is also seen in
A*6801 but not A*0201 . The sequences of several individ-
ual ligands confirm these pool sequences and clearly show
the mixed Val/Gln/Leu anchor of A*0214 (Fig. 4) .
We have established a series of ClR transfectant cell
lines that has facilitated the study of peptide binding and
presentation of HLA-A2 subtypes. The results of the pep-
tide binding experiments show that three A*0201-restricted
peptides bind well to A*0202, but much less well (or not at
all) to A*0205 and A*0214. This assay was used because of
its sensitivity, only requiring peptides in the 10-1° to 10-8 M
185 1
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(hsp90)
(human MHc I alpha)
A*0216
A*6801
Position
(gamma actin)
V (elongation factor)
Figure 4.
￿
Sequences of peptides eluted from CIR transfectants. Both
pool motifs and individual ligands are shown. The pool sequences of
A*0201 and A*6801 (6, 33) are included for comparison, and a similar
pool sequence of A*0205 has been previously reported (9).
range, which is much less than is required by many other
MHC/peptide binding assays. The peptides studied dif-
fered in their degree of specificity, with the gag peptide to-
tally A*0201/02 specific (according to this assay) and the
flu matrix peptide also reactive to A*0205 (weakly) and
A*6901 (strongly). This result coincides with the previous
anchors
1 2
VQ
L
3 4 5 6
IL
7 8 9
L
VF
preferred FY A IL DE KN RY VM
VA MD PG
YP K
ligands F V L P E L P S V (expressed sequence tag)
Y V I S V V F R L (connexin 32)
F Q L E I N V R L (unknown)
F Q L D D L K V E L (L35 ribosomal protein)
H L P S D F T P A V (bovine hemoglobin)
I L M E H I H K L (60S ribosomal protein)
F A Y D G K D Y I (MHC I alpha chain)
F A Y D G K D Y L (HLA-E precursor)
8 T L H L V R L (ubiquitin)
A*0201
Position
1 2 3 4 5 6 7 8 9
anchors L V
M V L
A*0202
Position
1 2 3 4 5 6 7 8 9
anchors L L
preferred AF A FA ED I IL HQ V
GV
I
VT
A*0205
Position
1 2 3 4 5 6 7 8 9
anchors V L
QL I
preferred FV I IM DE LV HQ YK
YA YP KG V
P
ligands A V P D E I P P L
FAY D G K D Y I
Position
1 2 3 4 5 6 7 8 9
anchors VT RK
DE
A*6901
Position
1 2 3 4 5 6 7 8 9
anchors VT VL
A IF IF
LM L
preferred E VY DE P V YR M
RP Q
ligands E T F N T P A H Y V
E T V A V G V I K AFigure 5 .
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Views of the B pocket through the al helix ofA*0201 (5), A*6801 (36), and the model ofA*0205/0214 . The A*0201 and A*6801 struc-
tures are taken directly from the published coordinates, and the modeled B pocket ofA*0205/0214 was generated by a substituting Tyr-9 for Phe-9 in
the A*0201 structure. The images were generated using Molscript (38) . The HLA main-chair and key side-chain residues are depicted in green, and the
bound peptide is represented in white with nitrogens in blue and oxygens in red. (A) A*0201 complexed with the HIV reverse transcriptase peptide,
showing the P2-Leu peptide anchor residue interacting with a hydrophobic B pocket (5) . This B pocket structure is probably very similar in A*0202 . (B)
A*6801 complexed with the influenza peptide, showing the P2-Val peptide anchor residue in the B pocket (36) . This B pocket structure is probably very
similar in A*6901 . (C) Modeled structure ofA*0205 or A*0214 showing the Val-67 conformation ofA*0201, the Tyr-9 residue in the same orientation
as the Phe-9 ofA*0201, and a P2-Gln peptide anchor residue in the B pocket. Possible hydrogen-bonding contacts are shown with dotted lines . It is pos-
sible that the Tyr-9 and Val-67 residues will adopt orientations similar to those shown in B when A*0205/0214 has a P2-Val peptide anchor .
1852
￿
Peptide Presentation by HLA-A2 Subtypesfinding that some flu matrix-specific, A*0201-restricted CTL
clones can also recognize HLA-A69 cells pulsed with this
peptide (34) . The sequences of eluted peptides coincide
well with the peptide binding assays and show that A*0202
has a very similar peptide motif compared with A*0201,
but that A*0205, A*0214, and A*6901 have significantly
different motifs. The CTL experiments show that some
CTLs are subtype specific whereas others cross-react
among a number of subtypes.
As indicated in the data summary in Table 1, position 9
ofthe HLA-A2, A68, and A69 molecules can be either Phe
or Tyr. The alleles that have Phe-9 have a Leu P2 peptide
anchor, but the alleles that have Tyr-9 generally have a
smaller and/or polar P2 residue (Val and either Gln, Thr,
or Ala). A*0205 and A*0214 also have some leucine in the
P2 anchor, suggesting that the B pocket of these alleles
might be able to adopt different structures to accommodate
these different residues. Position 9 of the MHC is in the
bottom ofthe B pocket of the peptide-binding groove, and
thus it is not surprising to find that this position greatly af-
fects the P2 anchor of the bound peptides (4, 5) . A com-
parison of the peptides that bind to A*0202 and A*0205,
which differ only in this one residue (actually only one ox-
ygen atom), demonstrates that this Phe-9 to Tyr-9 change
alone is sufficientto alter the specificity of the B pocket and
the nature of bound peptides.
The data implicating the relevance of position 9 of the
MHC in peptide binding coincides well with the reported
high resolution HLA crystal structures. The structures of
A*0201 and A*6801 show that the different P2 anchors of
these molecules are the result oftwo factors: the amino acid
difference at position 9 of the MHC and the rotamer con-
formational shift of Val-67 (35, 36). Fig. 5, A and B, shows
the B pocket of A*0201 and A*6801 with a P2-Leu and a
P2-Val, respectively (using the structural coordinates pro-
vided by references 5 and 36) . We predict that the B pocket
of A*0202 will be very similar to A*0201 and that the B
pocket of A*6901 will be similar to A*6801 . A comparison
of these crystal structures shows that the Csz atom of the
P2-Leu in A*0201 packs very closely to Phe-9 in a space
that is occupied by the hydroxyl group of Tyr-9 in the cor-
responding location in the A*6801 structure (35). In addi-
tion, the Val-67 orientation in A*6801 sterically blocks the
innermost part of the B pocket (35). It is likely that residue
9 has a significant effect in determining the hydrophobic or
hydrophilic nature of the B pocket, whereas the shift of
Val-67 has a largely steric effect that determines the size of
peptide side chains that fit in the B pocket.
Fig. 5 C shows a modeled B pocket structure ofA*0205/
0214 with a P2-Gln peptide anchor. This model was gen-
erated using the computer graphics program FRODO (37)
and visualized with Molscript version 1 .4 (38) . It involves a
Phe to Tyr substitution of the A*0201 B pocket structure,
and the Val-67 and Tyr-9 orientations allow a P2-Gln to fit
with possible hydrogen bonds (-2.5 A in length) to the
hydroxyl group of Tyr-9 and the main-chain nitrogen of
Val-67. Such a B pocket structure might also accommodate
a P2-Leu. A P2-Val, however, might require the Val-67
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Table 1.
￿
Summary ofPeptide Binding and Peptide
Sequencing Data
Note the correlation between residue 9 ofthe MHC and position 2 an-
chor of the associated peptide. Some pool sequence data involving
A*0201, A*0205, and A*6801 (6, 9, 33) have been included for com-
parison.
and Tyr-9 orientations seen in A*6801 (Fig. 5 B) . Confor-
mational shifts of MHC residues to accommodate different
peptide anchors have been observed in the single-peptide
crystal structures of HLA-A2 (5) and HLA-1353 (Smith, K.,
S. W. Reid, K. Harlos, A. J. McMichael, D. 1. Stuart, J.
Bell, and E. Y. Jones, manuscript submitted for publica-
tion)
The data in this study also coincide well with reports of
functional studies involving variant A2 molecules. A previ-
ous pool sequencing of peptides eluted from A*0205 (9)
shows similar results to the pool motif presented in Fig. 4.
In addition, our conclusions corroborate the recent findings
of Sudo et al. (38a), which determined the peptide binding
motifs of other A2 subtypes and found that A*0204 (Phe-9)
and A*0207 (Phe-9) have a Leu P2 anchor, whereas
A*0206 (Tyr-9) has a Val/Gln P2 anchor. Furthermore,
the single-amino acid substitution (Phe-9 to Tyr-9) in the
A*0201 molecule was investigated in a number of reports.
This mutant was shown to diminish dramatically binding of
the HIV pol and influenza matrix peptides (23, 39) and also
to abolish or abrogate CTL reactivity (23, 39-41) . Analyses
of large panels of influenza matrix-specific CTLs demon-
strate that most, but not all, clones and lines fail to recognize
this mutant (42, 43). The low level of peptide binding (23,
39) and the rare CTL recognition (42, 43) observed with
this mutant are consistent with the data in this report show-
ing a low cross-reactivity of A*0201-restricted peptides to
A*0205 and A*0214 and a low level of leucine at the P2
position ofpeptides eluted from these alleles.
In contrast with these findings, two other groups have
recently suggested that the peptide binding properties among
A2 subtypes actually are very similar (44-46) . One group
has studied the binding of the HBV core peptide 18-27 on
whole PHA-blast cells isolated from PBLs (44). They re-
port cross-reactivity of this peptide with many alleles (in-
cluding A*0201, A*0202, A*0205, A*0206, A*6802, and
A*6901) and define this group to be an A2-like "supertype"
Allele Residue 9
Capable of
pol gag
binding
matrix
Peptide
P2 P9
A*0201 F ++ ++ ++ L VL
A*0202 F ++ ++ + L L
A*0205 Y - - +/- VQL L
A*0214 Y - - - VQL L
A*6901 Y - - ++ VT VL
A*6801 Y ND ND ND VT RK
B*0701 - - -that all share a common peptide binding motif (hydropho-
bic residues at position 2 and the COOH terminus). The
other group (45, 46) has also reported a broad cross-reac-
tivity ofpeptide binding among the A2 subtypes and other
HLA-A locus alleles using a novel heavy chain refolding as-
say. Perhaps the individual peptides studied by these groups
possess an unusual degree of cross-reactivity, but there is no
evidence ofbroad CTL cross-reactivities among these HLA
molecules. In fact, the A*0202 and A*0205 subtypes were
first identified because they failed to present the influenza
matrix peptide to influenza-specific CTL (47-49). Our re-
sults support the view that different peptides have different
degrees of cross-reactivity among these alleles, and in our
peptide binding assay the HBV peptide has a low level of
cross-reactivity. It is also possible that the various in vitro
binding/folding assays have different stringencies that de-
pend on the conditions, concentrations, and approaches used.
However, considering that these alleles have different pool
sequence motifs, different individual peptides presented by
cells, different peptide binding properties, and different mod-
eled crystal structure B pockets, we believe that significant
functional differences exist in terms ofpeptide binding and
presentation. Some peptides are expected to be cross-reac-
tive, but others bind specifically to certain subtypes and not
to others.
The ability of the HLA-A2 subtypes to bind different
peptides has significant implications in the T cell response
in disease in vivo. By presenting different antigenic peptides
to CTL, these alleles are functionally distinct. Even the sub-
types that seem to present the same peptides (such as A*0201
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